Aldosterone antagonists for preventing the progression of chronic kidney disease

Cochrane Database of Systematic Reviews

Volumn , Issue 1, 2008, Pages

  Navaneethan, Sankar D ^a   Nigwekar, S U ^b   Strippoli, G F M ^b  

^a UNIVERSITY OF ROCHESTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE ANTAGONIST; ANGIOTENSIN RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; PLACEBO;

ALBUMINURIA; CARDIOVASCULAR DISEASE; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CREATININE BLOOD LEVEL; DISEASE COURSE; FOLLOW UP; GLOMERULUS FILTRATION RATE; GYNECOMASTIA; HOSPITALIZATION; HUMAN; HYPERKALEMIA; KIDNEY FUNCTION; MORTALITY; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL; REVIEW;

EID: 44949193914     PISSN: 1469493X     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD007004     Document Type: Review

References (27)

1. Aldigier 2005 Aldigier JC, Kanjanbuch T, Ma LJ, Brown NJ, Fogo AB. Regression of existing glomerulosclerosis by inhibition of aldosterone. Journal of the Amercian Society of Nephrology 2005;16(11):3306-14. [MEDLINE: 16192423].
2. Bianchi 2006 Bianchi S, Bigazzi R, Campese VM. Long-term effects of spironolactone on proteinuria and kidney function in patients with chronic kidney disease. Kidney International 2006;70(12):2116-23. [MEDLINE: 17035949].
3. Brenner 2001 Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, et al.Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. New England Journal of Medicine 2001;345(12):861-9. [MEDLINE: 11565518].
4. Brenner 2003 Brenner B. Retarding the progression of renal disease. Kidney International 2003;64(1):370-8. [MEDLINE: 12787440].
5. Chrysostomou 2006 Chrysostomou A, Pedagogos E, MacGregor L, Becker GJ. Double-blind, placebo-controlled study on the effect of the aldosterone receptor antagonist spironolactone in patients who have persistent proteinuria and are on long-term angiotensin-converting enzyme inhibitor therapy, with or without an angiotensin II receptor blocker. Clinical Journal of The American Society of Nephrology: CJASN 2006; 1(2):256-62. [MEDLINE: 17699214].
6. Dickersin 1994 Dickersin K, Scherer R, Lefebvre C. Identifying relevant studies for systematic reviews. BMJ 1994;309(6964):1286- 91. [MEDLINE: 7718048].
7. Epstein 2006 Epstein M, Williams GH, Weinberger M, Lewin A, Krause S, Mukherjee R, et al.Selective aldosterone blockade with eplerenone reduces albuminuria in patients with type 2 diabetes. Clinical Journal of The American Society of Nephrology: CJASN 2006;1(5):940-51. [MEDLINE: 17699311].
8. GISEN 1997 The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia). Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. Lancet 1997;349 (9069):1857-63. [MEDLINE: 9217756].
9. Grassmann 2005 Grassmann A, Gioberge S, Moeller S, Brown G. ESRD patients in 2004: global overview of patient numbers, treatment modalities and associated trends. Nephrology Dialysis Transplantation 2005;20(12): 2587-93. [MEDLINE: 16204281].
10. Green 1996 Greene EL, Kren S, Hostetter TH. Role of aldosterone in the remnant kidney model in the rat. Journal of Clinical Investigation 1996;98(4): 1063-8. [MEDLINE: 8770880].
11. Higgins 2003 Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency inmeta-analyses. BMJ 2003;327(7414):557- 60. [MEDLINE: 12958120].
12. Hostetter 2003 Hostetter TH, Ibrahim HN. Aldosterone in chronic kidney and cardiac disease. Journal of the American Society of Nephrology 2003;14 (9):2395-401. [MEDLINE: 12937319].
13. Jafar 2001 Jafar TH, Schmid CH, Landa M, Giatras I, Toto R, Remuzzi G, et al.Angiotensin-converting enzyme inhibitors and progression of non-diabetic renal disease. A meta-analysis of patient-level data. Annals of Internal Medicine 2001;135(2):73-87. [MEDLINE: 11453706].
14. Juurlink 2004 Juurlink DN, Mamdani MM, Lee DS, Kopp A, Austin PC, Laupacis A, et al.Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study. New England Journal of Medicine 2004;351(6):543-51. [MEDLINE: 15295047].
15. Klahr 1994 Klahr S, Levey AS, Beck GJ, Caggiula AW, Hunsicker L, Kusek JW, et al.The effects of dietary protein restriction and blood-pressure control on the progression of chronic renal disease. Modification of Diet in Renal Disease Study Group. New England Journal of Medicine 1994; 330(13):877-84. [MEDLINE: 8114857].
16. Lefebvre 1996 Lefebvre C, McDonald S. Development of a sensitive search strategy for reports of randomized controlled trials in EMBASE. Fourth International Cochrane Colloquium; 1996 Oct 20-24; Adelaide (Australia). 1996.
17. Master List 2007 United States Cochrane Center. Master list of journals being searched. http://apps1.jhsph.edu/cochrane/masterlist.asp (accessed MAy 2007).
18. Mathiesen 1999 Mathiesen ER, Hommel E, Hansen HP, Smidt UM, Parving HH. Randomised controlled trial of long term efficacy of captopril on preservation of kidney function in normotensive patients with insulin dependent diabetes and microalbuminuria. BMJ 1999;319(7201): 24-5. [MEDLINE: 10390455].
19. Pitt 1999 Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, et al.The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. New England Journal of Medicine 1999;1999(341):10. [MEDLINE: 10471456].
20. Pitt 2003 Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B, et al.Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. New England Journal of Medicine 2003;348(14):1309-21. [MEDLINE: 12668699].
21. Rocha 1998 Rocha R, Chander PN, Khanna K, Zuckerman A, Stier CT Jr. Mineralocorticoid blockade reduces vascular injury in stroke-prone hypertensive rats. Hypertension 1998;31(1 Pt 2):451-8. [MEDLINE: 9453344].
22. Rossing 2004 Rossing K, Schjoedt KJ, Smidt UM, Boomsma F, Parving HH. Beneficial effects of adding spironolactone to recommended antihypertensive treatment in diabetic nephropathy: a randomized, double-masked, cross-over study. Diabetes Care 2005;28(9):2106-12. [MEDLINE: 16123474].
23. Schieppati 2003 Schieppati A, Remuzzi G. The June 2003 Barry M. Brenner Comgan lecture. The future of renoprotection: frustration and promises. Kidney International 2003;64(6):1947-55. [MEDLINE: 14633117].
24. Schjoedt 2005 Schjoedt KJ, Rossing K, Juhl TR, Boomsma F, Rossing P, Parving HH. Beneficial impact of spironolactone in diabetic nephropathy. Kidney International 2005;68(6):2829-36. [MEDLINE: 16316360].
25. Silvestre 1998 Silvestre JS, Robert V, Heymes C, Aupetit-Faisant B, Mouas C, Moalic JM, et al.Myocardial production of aldosterone and corticosterone in the rat. Physiological regulation. Journal of Biological Chemistry 1998;273(9):4883-91. [MEDLINE: 9478930].
26. Staessen 1981 Staessen J, Lijnen P, Fagard R, Verschueren LJ, Amery A. Rise in plasma concentration of aldosterone during long-term angiotensin II suppression. Journal of Endocrinology 1981;91(3): 457-65. [MEDLINE: 7035596].
27. Strippoli 2006 Strippoli GF, Bonifati C, Craig M, Navaneethan SD, Craig JC. Angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists for preventing the progression of diabetic kidney disease. Cochrane Database of Systematic Reviews 2006, Issue 4.Art. No.: CD006257. DOI:10.1002/14651858.CD006257.